Management of Basal Insulin in NPO Patients with Hyperglycemia

Rationale for Continuing Basal Insulin

The American Diabetes Association recommends continuing basal insulin (Lantus) even when a patient is NPO to prevent further hyperglycemia and potential metabolic decompensation 1
For patients who are NPO or have poor oral intake, a basal plus correction insulin regimen is the preferred treatment approach rather than withholding insulin, as recommended by the American Diabetes Association 1
The American Diabetes Association strongly discourages the use of sliding scale insulin (SSI) alone as the sole method of insulin treatment in hospitalized patients 1
Maintaining consistent basal insulin administration is crucial for stable blood glucose control between meals and overnight, according to the American Association of Clinical Endocrinologists 2

For hyperglycemic patients who are NPO, the American Diabetes Association recommends continuing the scheduled basal insulin (Lantus) and adding correction insulin as needed based on blood glucose monitoring 1, 3
The American Diabetes Association suggests monitoring blood glucose every 4-6 hours in NPO patients 4
The American Diabetes Association advises against using only sliding scale insulin without basal coverage in hospitalized patients 1, 5
For patients with a blood glucose of over 300 mg/dL, the American College of Physicians recommends that insulin therapy should not be delayed 6

In perioperative settings, the American Diabetes Association recommends giving 75-80% of the usual dose of long-acting insulin analogs like Lantus when the patient is NPO 3
For patients with blood glucose over 300 mg/dL, the American College of Physicians recommends that insulin therapy should not be delayed 6

The American Diabetes Association recommends continuing to monitor blood glucose every 4-6 hours while the patient remains NPO 4
If the patient remains NPO and requires ongoing glycemic management, the American Association of Clinical Endocrinologists suggests continuing intravenous fluids if appropriate and supplementing with subcutaneous correction-dose insulin as needed 1, 4
The American Diabetes Association advises considering adjusting the basal insulin dose if hyperglycemia persists 1

The American Diabetes Association recommends avoiding withholding basal insulin in NPO patients, as this can lead to significant hyperglycemia and metabolic decompensation 1
The American Diabetes Association advises against relying solely on sliding scale insulin for glycemic control in hospitalized patients 1, 5
The American Association of Clinical Endocrinologists warns that abrupt discontinuation of insulin therapy can lead to poor glycemic control and potential complications 4